Longevity
NAD+ Injections vs. Oral Tablets: What the Evidence Actually Shows

NAD+ — nicotinamide adenine dinucleotide — is a molecule every living cell depends on to turn nutrients into usable energy. It also serves as fuel for enzymes involved in cell maintenance. Interest in supplementing it has grown quickly, and two products now dominate the conversation: oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and intravenous or injectable NAD+. The honest answer about which is better is more limited than most marketing suggests, because the two have barely been compared to each other in people.
Why NAD+ is difficult to raise directly
NAD+ is not stored like a vitamin. Cells make it continuously and consume it continuously, and a large oral dose of NAD+ itself is largely broken down during digestion before it reaches the bloodstream. That is why most supplements supply precursors — smaller molecules the cell can convert into NAD+ — rather than NAD+ itself.
Injectable NAD+ sidesteps digestion. An intravenous infusion delivers the molecule into the bloodstream directly, so measured blood levels rise during and shortly after the infusion. Whether that transient rise translates into lasting tissue NAD+ in the organs that matter, and whether it produces any clinical benefit, are separate questions that a blood level cannot answer.
What oral precursors have shown in people
Human trials of nicotinamide riboside and nicotinamide mononucleotide have consistently shown that these compounds can raise NAD+ or its metabolites in blood and, in some studies, in tissue samples. Short-term trials in generally healthy adults have generally described them as well tolerated at studied doses.
The clinical picture is less settled. A 2025 review in Nature Metabolism of NAD+ precursor supplementation in human ageing concluded that the evidence for meaningful clinical benefits in healthy older adults remains limited, and that the field needs larger, longer trials with clinically meaningful endpoints rather than blood measurements alone. In other words, raising a lab value has been demonstrated; improving how a person feels, functions, or ages has not been established.
What injectable NAD+ has shown
Intravenous NAD+ is widely offered by wellness clinics, but the controlled human research behind it is thin. A 2026 pilot study in Frontiers in Aging directly compared an intravenous NAD+ infusion with an oral NAD+ precursor in people and tracked how blood markers changed — exactly the head-to-head comparison that has been largely missing from the literature. Small pilot studies like this describe what happens to measured levels; they are not proof of a clinical benefit.
Systematic assessments of the area have noted the same gap: rigorous trials testing injectable NAD+ for aging-related outcomes are scarce, so claims about energy, cognition, or reverse ageing rest largely on animal work, lab measurements, and personal reports.
Reasons people choose one or the other
- Oral tablets or capsules are inexpensive per dose, can be taken at home, and suit patients who want a consistent daily approach rather than clinic visits.
- Injectable NAD+ avoids the digestive step, is administered under clinical supervision in a single session, and suits patients who prefer a supervised, occasional treatment.
- Cost and time differ sharply: a daily tablet is a recurring small expense, while an infusion is a larger per-session cost that requires clinic time.
- Tolerability is also different. Niacin-flush-type reactions, nausea, or flushing are reported with some oral precursors at higher doses; infusions can cause warmth, flushing, nausea, or discomfort at the IV site during the infusion.
Questions worth asking before you pay
- What specific outcome is this being used for, and is there human trial evidence for that outcome at this dose?
- Is the dose in the product or infusion the same dose studied in trials, and how does it compare with the doses used in the research cited above?
- What will be measured before and after to decide whether it is helping you, and over what time frame?
- What else — sleep, thyroid and iron status, vitamin D, exercise, medication review — should be evaluated first if fatigue is the reason you are seeking it?
What Vitality Modern Medicine offers
In clinic, NAD+ is available as a supervised booster injection: 50 mg for $30 and 100 mg for $60, and IV infusions start at $129. Every injection or infusion begins with a brief health screening and a conversation about what you are hoping to get from it, and it is only administered when a provider determines it is appropriate for you.
If you are pursuing fatigue, low energy, or cognitive complaints, those symptoms are usually evaluated before any supplement is recommended, because they have many treatable causes that a lab value can mask. Online hormone-care patients are evaluated in that order: labs first, then a provider review, then a plan.
Prices shown are current clinic prices as of October 2026, are cash-pay, and can change. A provider decides whether a specific injection or supplement is appropriate for you before anything is administered.
This article summarizes published research for general education. It is not medical advice, does not recommend a specific product or dose, and does not replace evaluation by your own provider.
References
- NAD+ precursor supplementation in human ageing: clinical evidence and challenges — Nature Metabolism review (2025)
- Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge — review (Journals of Gerontology)
- Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus oral nicotinamide riboside — pilot study, Frontiers in Aging (2026)
Related program
In-Person Care
Explore the related provider-led program and available treatment pathways.
See the programThis article is general education, not medical advice, and does not create a provider-patient relationship. Treatment is prescribed only when a Vitality provider determines it is medically appropriate.